MaxCyte

MaxCyte, Inc. is a life sciences company based in Rockville, Maryland, founded in 1999. The company specializes in non-viral cell engineering technologies and went public on July 30, 2021. MaxCyte is known for its Flow Electroporation® technology, which allows for the efficient delivery of biomolecules into cells without using viral vectors. This technology supports various applications, including cell and gene therapy development, drug discovery, gene editing, and biomanufacturing. The ExPERT™ platform is a key offering from MaxCyte, featuring several systems for different scales of transfection, including ExPERT ATx for small-to-medium scale, ExPERT STx for protein production, ExPERT GTx for large-scale therapeutic applications, and ExPERT VLx for very large-volume cell engineering. The company also provides consumables such as disposable processing assemblies and electroporation buffers. MaxCyte collaborates with biopharmaceutical companies, academic institutions, and translational centers worldwide, enhancing their R&D efforts while maintaining high efficiency and cell viability.